Home › Research › What the research found › Every row
Every row of the evidence table
One row per finding: what was tested, which way the result went, and how the study was built. The answer by area, and where the studies disagree, are on the main page.
Every row
Filter
Showing 6 of 382 rows for Psychotropics for agitation / psychosis. One row per study per exposure: a study that tested two different things appears twice, once for each.
Scroll the table sideways to see every column.
| Exposure | Question | Direction | Outcome measured | Design | People | Effect size, as the source reported it | Source |
|---|---|---|---|---|---|---|---|
| Psychotropics for agitation / psychosis Medicines | Treatment |
Benefit
whyThe NPI-C agitation/aggression measure did not reach significance (p=0.094). |
Pittsburgh Agitation Scale over 3 weeks | phase 2 trial | 75 | PAS decline difference -0.74/week (p=0.015, ES 0.53); NPI-C A/A -1.26/week (p=0.094, ES 0.36) |
The American Journal of Geriatric Psychiatry
2026 ✓ Peer-reviewed PMID 41350162 |
| Psychotropics for agitation / psychosis Medicines | Treatment |
No effect
whyNot effective, and drug-related QT prolongation was observed. The randomised sample was smaller than planned. |
Clinically significant improvement in agitation at 12 weeks | phase 3 trial | 173 | Risk difference for clinically significant improvement 0.08 (95% CI -0.21 to 0.06) |
Nature Medicine
2025 ✓ Peer-reviewed PMID 40133524 |
| Psychotropics for agitation / psychosis Medicines | Treatment |
No direction reported
whyA feasibility trial in 29 residents: designed to test whether the trial can be run, not powered for efficacy, and it reports no efficacy estimate. |
Feasibility, adherence and safety | randomised trial | 29 | 100% adherence; no withdrawals; 0 adverse reactions |
Age and Ageing
2025 ✓ Peer-reviewed PMID 40479610 |
| Psychotropics for agitation / psychosis Medicines | Treatment |
Benefit
whyThe authors describe the reduction as small (-1.32 points). |
NPI apathy score at 6 weeks | phase 2 trial | 94 | NPI apathy change -1.32 points (95% CI -2.43 to -0.21) vs placebo |
The Lancet Neurology
2025 ✓ Peer-reviewed PMID 39862881 |
| Psychotropics for agitation / psychosis Medicines | Treatment |
Benefit
whyA post hoc dementia subgroup of a randomised-withdrawal trial that was not designed or powered for it; 46 randomised responders. The authors say to read it cautiously. |
Psychosis relapse over up to 26 weeks | phase 3 trial | 76 | Psychosis relapse HR 0.031 (95% CI 0.010-0.103) vs placebo among 46 randomised responders |
BMC Neurology
2025 ✓ Peer-reviewed PMID 41286676 |
| Psychotropics for agitation / psychosis Medicines | Treatment |
Benefit
whyBoth doses beat placebo. Treatment-emergent adverse events were more common than placebo (84.6% at 2 mg, 76.8% at 1 mg, 73.8% placebo). |
Cohen-Mansfield Agitation Inventory at week 10 | phase 3 trial | not stated | CMAI change vs placebo: -7.2 (95% CI -10.0 to -4.3) at 2 mg; -3.7 (95% CI -6.8 to -0.7) at 1 mg |
Alzheimer's & Dementia
2024 ✓ Peer-reviewed PMID 39369280 |
Last updated